Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Genitourinary tumours, prostate

3437 - Abiraterone acetate (AA) followed by randomization to dasatinib (D) or sunitinib malate (S) in metastatic castrate resistant prostate cancer (mCRPC)


09 Oct 2016


Genitourinary tumours, prostate


Eleni Efstathiou


Annals of Oncology (2016) 27 (6): 243-265. 10.1093/annonc/mdw372


E. Efstathiou1, A. Tsikkinis2, S. Wen1, E. Li Ning Tapia1, A. Hoang1, A. Aparicio1, S. Tu1, G. Rangel1, P. Troncoso1, P. Corn1, J. Araujo1, C. Logothetis1

Author affiliations

  • 1 Genitourinary Medical Oncology, MD Anderson Cancer Center, 77030-3721 - Houston/US
  • 2 Genitourinary Medical Oncology, MD Anderson Cancer Center, 77030 - Houston/US


Abstract 3437


Src and Vegf, targeted by D and S respectively, have been implicated in CRPC progression. Moreover the unmet need for predictive markers has become pressing. We conducted a study to determine if the addition of either agents could prolong time to progression (TTP) on AA and to test a prespecified molecular signature.


This is a phase II study of AA in bone mCRPC patients randomized upon progression to combination with D or S, comparing the two treatment strategy. Endpoints include PFS, safety, survival, assessment of aprespecified signaling signature in pts with benefit vs primary resistance to AA (progression ≤ 4 months). Pts had pretreatment bone biopsy. Tumor Markers included, Androgen Receptor-N terminal (AR-N), AR-C terminal (AR-C), CYP17, Ki67, GR, ERG, Ki67 (%), pSrc, vegf, DNA repair genes by IHC and steroids by LCMS.


Study (03/2011-02/2015) accrued 179 bone mCRPC pts and median follow up 27ms (9-57). Medians: Age, 68 ys (range 45-87), PS ECOG 1 (range 0-1) baseline PSA 20.6 (range 0.5-1655). 27 (16%) pts have visceral mets, 40 (22%) prior chemo. Diagnostic Gleason Score was ≥8 in 71%. Upon progression 128/179 pts were randomized: 64 to D (AD) and 64 to S (AS). Of these 61 crossed over and 30 are still on treatment. Fifty Five pts had primary resistance to AA. Thirteen pts discontinued due to adverse events (2 AA, 6AD and 5 AS) Median (CI 95%) TTP and Overall Survival (OS) for the cohort are 12.85 (11.08, 14.98 ) and 26.26 ( 23.21, 31.93 ) ms respectively. There is no difference for drug sequence. On multivariate analysis, primary resistance to AA (p


D or S do not improve AA efficacy or overcome primary resistance. Validation of prespecified androgen signaling signature predictive of AA response is planned in a multi-institutional study.

Clinical trial identification


Legal entity responsible for the study

MD Anderson Cancer Center




E. Efstathiou: research support, ad board honoraria; Janssen, Astellas, Sanofi, Medivation, Takeda.

C. Logothetis: Research: BMS, Medivation, Sanofi, Astellas, Janssen. Advisory boards: Astellas, AstraZeneca, Janssen, Sanofi, Bayer, Medivation, Clovis, Oncology, Churchill Pharmaceuticals.

All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings